Zhong Guo Jing Ji Wang·2025-10-24 06:12Core Viewpoint - The financial performance of YaoYigou (药易购) for the first three quarters of 2025 shows a slight increase in revenue but significant losses in net profit and cash flow, indicating potential challenges in operational efficiency and profitability [1][2]. Financial Performance Summary - For the first nine months of 2025, the company achieved a revenue of 3.242 billion yuan, representing a year-on-year growth of 0.21% [1][2]. - The net profit attributable to shareholders was -8.36 million yuan, a decline of 159.98% compared to the same period last year, which reported a profit of 13.93 million yuan [1][2]. - The net profit after excluding non-recurring items was -10.15 million yuan, down 208.41% from the previous year's profit of 9.37 million yuan [1][2]. - The net cash flow from operating activities was -114.16 million yuan, a significant decrease of 397.91% compared to the previous year's cash flow of 38.32 million yuan [1][2]. Initial Public Offering (IPO) Details - YaoYigou was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 27, 2021, with an issuance of 23.92 million shares at a price of 12.25 yuan per share, raising a total of 293 million yuan [3]. - The net amount raised after deducting issuance costs was 249 million yuan, which was 196 million yuan less than the original plan of 445 million yuan [3]. Previous Year Comparison - In 2024, the company reported a revenue of 4.381 billion yuan, a decrease of 1.12% year-on-year [4]. - The net profit attributable to shareholders for 2024 was 16.36 million yuan, down 72.52% from the previous year [4]. - The net profit after excluding non-recurring items was 12.37 million yuan, a decline of 77.10% compared to the previous year [4]. - The net cash flow from operating activities for 2024 was 128 million yuan, an increase of 210.58% year-on-year [4].